Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc., 19085-19086 [2017-08344]
Download as PDF
<![CDATA[
19085
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
Controlled substance
Drug code
Codeine ..........................................................................................................................................................................
Oxycodone .....................................................................................................................................................................
Hydromorphone .............................................................................................................................................................
Hydrocodone ..................................................................................................................................................................
Methadone .....................................................................................................................................................................
Methadone intermediate ................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ............................................................................................................
Morphine ........................................................................................................................................................................
Oripavine ........................................................................................................................................................................
Thebaine ........................................................................................................................................................................
Opium tincture ...............................................................................................................................................................
Oxymorphone ................................................................................................................................................................
The company plans to manufacturer
the listed controlled substances in bulk
for distribution to its customers.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before June 26, 2017.
DATES:
Dated: April 18, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–08347 Filed 4–24–17; 8:45 am]
Drug Enforcement Administration
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
[Docket No. DEA–392]
SUPPLEMENTARY INFORMATION:
ADDRESSES:
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Bulk Manufacturer of Controlled
Substances Application: Sigma Aldrich
Research Biochemicals, Inc.
ACTION:
Notice of application.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Drug code
Cathinone .......................................................................................................................................................................
Methcathinone ...............................................................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ..................................................................................................................
Aminorex ........................................................................................................................................................................
Alpha-ethyltryptamine ....................................................................................................................................................
Lysergic acid diethylamide ............................................................................................................................................
Tetrahydrocannabinols ..................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine ............................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine ........................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine ............................................................................................................................
2,5-Dimethoxyamphetamine ..........................................................................................................................................
3,4-Methylenedioxyamphetamine ..................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine .....................................................................................................................
3,4-Methylenedioxymethamphetamine ..........................................................................................................................
Dimethyltryptamine ........................................................................................................................................................
Psilocybin .......................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine .............................................................................................................................
N-Benzylpiperazine ........................................................................................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) .....................................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) ....................................................................................................
Heroin ............................................................................................................................................................................
Normorphine ..................................................................................................................................................................
Norlevorphanol ...............................................................................................................................................................
Amphetamine .................................................................................................................................................................
Methamphetamine .........................................................................................................................................................
Nabilone .........................................................................................................................................................................
1-Phenylcyclohexylamine ..............................................................................................................................................
Phencyclidine .................................................................................................................................................................
Cocaine ..........................................................................................................................................................................
Codeine ..........................................................................................................................................................................
Ecgonine ........................................................................................................................................................................
17:42 Apr 24, 2017
Jkt 241001
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
December 19, 2016, Sigma Aldrich
Research Biochemicals, Inc., 1–3
Strathmore Road, Natick, Massachusetts
01760–2447 applied to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Controlled substance
VerDate Sep<11>2014
9050
9143
9150
9193
9250
9254
9273
9300
9330
9333
9630
9652
Schedule
E:\FR\FM\25APN1.SGM
25APN1
1235
1237
1248
1585
7249
7315
7370
7391
7392
7395
7396
7400
7402
7404
7405
7435
7437
7439
7470
7493
7535
7540
9200
9313
9634
1100
1105
7379
7460
7471
9041
9050
9180
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
19086
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
Controlled substance
Drug code
Levomethorphan ............................................................................................................................................................
Levorphanol ...................................................................................................................................................................
Meperidine .....................................................................................................................................................................
Metazocine .....................................................................................................................................................................
Methadone .....................................................................................................................................................................
Morphine ........................................................................................................................................................................
Thebaine ........................................................................................................................................................................
Levo-alphacetylmethadol ...............................................................................................................................................
Remifentanil ...................................................................................................................................................................
Sufentanil .......................................................................................................................................................................
Carfentanil ......................................................................................................................................................................
Fentanyl .........................................................................................................................................................................
The company plans to manufacture
reference standards.
Dated: April 18, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–08344 Filed 4–24–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1121–0064]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Currently Approved Collection: Annual
Parole Survey, Annual Probation
Survey
Bureau of Justice Statistics,
Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice
(DOJ), Office of Justice Programs,
Bureau of Justice Statistics, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until June
26, 2017.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Danielle Kaeble, Statistician, Bureau of
Justice Statistics, 810 Seventh Street
NW., Washington, DC 20531 (email:
Danielle.Kaeble@usdoj.gov; telephone:
202–305–2017).
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Extension of a currently approved
collection.
2. The Title of the Form/Collection:
Annual Parole Survey, Annual
Probation Survey.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
Form numbers for the questionnaire are
CJ–7 Annual Parole Survey; CJ–8
Annual Probation Survey; CJ–8a Annual
Probation Survey (Short Form). The
applicable component within the
Department of Justice is the Bureau of
Justice Statistics, in the Office of Justice
Programs.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: State departments of
corrections or state probation and parole
authorities.
Others: The Federal Bureau of
Prisons, city and county courts and
PO 00000
Frm 00071
Fmt 4703
Sfmt 9990
9210
9220
9230
9240
9250
9300
9333
9648
9739
9740
9743
9801
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
probation offices for which a central
reporting authority does not exist. For
the CJ–7 form, the affected public
consists of 53 respondents including 51
central reporters (two state respondents
in Pennsylvania, and one each from the
remaining states), the District of
Columbia, and the Federal Bureau of
Prisons responsible for keeping records
on parolees. For the CJ–8 form, the
affected public includes 305 reporters
including 35 state respondents, the
District of Columbia, the Federal Bureau
of Prisons, and 268 from local
authorities responsible for keeping
records on probationers. For the CJ–8A
form, the affected public includes 151
reporters who are all local authorities
responsible for keeping records on
probationers. The Annual Parole Survey
and Annual Probation surveys have
been used since 1977 to collect annual
yearend counts and yearly movements
of community corrections populations;
characteristics of the community
supervision population, such as gender,
racial composition, ethnicity, conviction
status, offense, and supervision status.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: 509 respondents each taking
an average of 1.63 hours to respond.
6. An estimate of the total public
burden (in hours) associated with the
collection: There is an estimated 830
total burden hours associated with this
collection.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE., 3E.405A,
Washington, DC 20530.
Dated: April 20, 2017.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2017–08342 Filed 4–24–17; 8:45 am]
BILLING CODE 4410–18–P
E:\FR\FM\25APN1.SGM
25APN1
]]>Agencies
[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Pages 19085-19086]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08344]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Sigma
Aldrich Research Biochemicals, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before June 26, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
December 19, 2016, Sigma Aldrich Research Biochemicals, Inc., 1-3
Strathmore Road, Natick, Massachusetts 01760-2447 applied to be
registered as a bulk manufacturer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Cathinone........................... 1235 I
Methcathinone....................... 1237 I
Mephedrone (4-Methyl-N- 1248 I
methylcathinone).
Aminorex............................ 1585 I
Alpha-ethyltryptamine............... 7249 I
Lysergic acid diethylamide.......... 7315 I
Tetrahydrocannabinols............... 7370 I
4-Bromo-2,5-dimethoxyamphetamine.... 7391 I
4-Bromo-2,5-dimethoxyphenethylamine. 7392 I
4-Methyl-2,5-dimethoxyamphetamine... 7395 I
2,5-Dimethoxyamphetamine............ 7396 I
3,4-Methylenedioxyamphetamine....... 7400 I
N-Hydroxy-3,4- 7402 I
methylenedioxyamphetamine.
3,4-Methylenedioxy-N- 7404 I
ethylamphetamine.
3,4-Methylenedioxymethamphetamine... 7405 I
Dimethyltryptamine.................. 7435 I
Psilocybin.......................... 7437 I
5-Methoxy-N,N-diisopropyltryptamine. 7439 I
1-[1-(2- 7470 I
Thienyl)cyclohexyl]piperidine.
N-Benzylpiperazine.................. 7493 I
MDPV (3,4- 7535 I
Methylenedioxypyrovalerone).
Methylone (3,4-Methylenedioxy-N- 7540 I
methylcathinone).
Heroin.............................. 9200 I
Normorphine......................... 9313 I
Norlevorphanol...................... 9634 I
Amphetamine......................... 1100 II
Methamphetamine..................... 1105 II
Nabilone............................ 7379 II
1-Phenylcyclohexylamine............. 7460 II
Phencyclidine....................... 7471 II
Cocaine............................. 9041 II
Codeine............................. 9050 II
Ecgonine............................ 9180 II
[[Page 19086]]
Levomethorphan...................... 9210 II
Levorphanol......................... 9220 II
Meperidine.......................... 9230 II
Metazocine.......................... 9240 II
Methadone........................... 9250 II
Morphine............................ 9300 II
Thebaine............................ 9333 II
Levo-alphacetylmethadol............. 9648 II
Remifentanil........................ 9739 II
Sufentanil.......................... 9740 II
Carfentanil......................... 9743 II
Fentanyl............................ 9801 II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
Dated: April 18, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-08344 Filed 4-24-17; 8:45 am]
BILLING CODE 4410-09-P
